Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, Charles J.

doi:10.1001/jama.1994.03510470040032

Cited by 790Sepsis Diagnosis and TreatmentInflammation biomarkers and pathwaysAntibiotics Pharmacokinetics and Efficacy

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, Charles J.·1994·JAMA

DOI 10.1001/jama.1994.03510470040032

Open this paper in CoChat — free account

Abstract

Objective. —To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design. —Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. Population. —A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Outcome Measure. —Twenty-eight—day all-cause mortality. Results. —There was not a significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication (n=893; generalized Wilcoxon statistic,P=.22) or among patients with shock at study entry (n=713; generalized Wilcoxon statistic,P=.23), the two primary efficacy analyses specified a priori for this trial. Results from secondary analyses suggest an increase in survival time with rhIL-1ra treatment among patients with dysfunction of one or more organs (n=563; linear dose-response,P=.009). Retrospective analysis demonstrated an increase in survival time with rhIL-1ra treatment among patients with a predicted risk of mortality of 24% or greater (n=580; linear dose-response,P=.005) as well as among patients with both dysfunction of one or more organs and a predicted risk of mortality of 24% or greater (n=411; linear dose-response,P=.002). Conclusions. —There was not a statistically significant increase in survivial time for rhIL-1ra treatment compared with placebo among all patients who received the study medication or among patients with shock at study entry. Secondary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater. (JAMA. 1994;271:1836-1843)

Integrity signals

Registry

Crossref · 10.1001/jama.1994.03510470040032

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Administration of monoclonal antibodies directed at specific cytokines and use of apheresis or medical devices to remove cytokines from circulation have had generally disappointing results in clinical trials for sepsis-associated cytokine storm.
“The administration of monoclonal antibodies directed at specific cytokines and the use of apheresis or medical devices to remove cytokines from circulation have had generally disappointing results in clinical trials.62”
From Cytokine storm (2020) · cites this paper as [62]

Sorted by citations

Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463 · see citing works
Cytokine storm
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196 · see citing works
Multiple Organ Dysfunction Score
Marshall, J. C., Cook, D. J., Christou, N. V., Bernard, G. R., Sprung, C. L., & Sibbald, W. J. (1995) · Critical Care Medicine · doi:10.1097/00003246-199510000-00007 · Cited by 2,531 · see citing works
Overview of the <scp>IL</scp> ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866 · see citing works
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C., Simon, A., & van der Meer, J. V. D. (2012) · Nature reviews. Drug discovery · doi:10.1038/nrd3800 · Cited by 1,813 · see citing works
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190 · see citing works
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., Metz, C., Miller, E. J., et al. (2004) · Nature Medicine · doi:10.1038/nm1124 · Cited by 1,170 · see citing works
Sepsis: A New Hypothesis for Pathogenesis of the Disease Process
Bone, R. C., Grodzin, C. J., & BALK, R. A. (1997) · CHEST Journal · doi:10.1378/chest.112.1.235 · Cited by 1,019 · see citing works
Sir Isaac Newton, sepsis, SIRS, and CARS
Bone, R. C. (1996) · Critical Care Medicine · doi:10.1097/00003246-199607000-00010 · Cited by 995 · see citing works
Sepsis: a roadmap for future research
Cohen, J., Vincent, J., Adhikari, N. K. J., Machado, F. R., Angus, D. C., Calandra, T., Jaton, K., Giulieri, S. G., Delaloye, J., Opal, S. M., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70112-x · Cited by 996 · see citing works
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Opal, S. M., Fisher, C. J., Dhainaut, J.-F., Vincent, J., Brase, R., Lowry, S. F., SADOFF, J. C., Slotman, G. J., Levy, H. A., BALK, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 867 · see citing works
Self-citation
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867 · see citing works
Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure
Fowler, A. A., Truwit, J. D., Hite, R. D., Morris, P. E., DeWilde, C., Priday, A., Fisher, B., Thacker, L. R., Natarajan, R., Brophy, D. F., et al. (2019) · JAMA · doi:10.1001/jama.2019.11825 · Cited by 836 · see citing works
Novel strategies for the treatment of sepsis
Riedemann, N. C., Guo, R., & Ward, P. A. (2003) · Nature Medicine · doi:10.1038/nm0503-517 · Cited by 774 · see citing works
Interleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor Antagonist
Dinarello, C. A. (1998) · International Reviews of Immunology · doi:10.3109/08830189809043005 · Cited by 761 · see citing works
Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis
Kolb, M. R. J., Margetts, P. J., Anthony, D. C., Pitossi, F. J., & Gauldie, J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12568 · Cited by 754 · see citing works
Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis
Fergusson, D., Aaron, S. D., Guyatt, G., & Hébert, P. (2002) · BMJ · doi:10.1136/bmj.325.7365.652 · Cited by 708 · see citing works
Anti-inflammatory therapies to treat sepsis and septic shock
Zéni, F., Freeman, B. D., & Natanson, C. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00001 · Cited by 656 · see citing works
Has the mortality of septic shock changed with time?
Friedman, G., Silva, E., & Vincent, J. (1998) · Critical Care Medicine · doi:10.1097/00003246-199812000-00045 · Cited by 597 · see citing works
Sepsis and the Heart
Merx, M. W., & Weber, C. (2007) · Circulation · doi:10.1161/circulationaha.106.678359 · Cited by 603 · see citing works
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation
Ulloa, L., Ochani, M., Yang, H., Tanovic, M., Halperin, D. M., Yang, R., Czura, C. J., Fink, M. P., & Tracey, K. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192222999 · Cited by 585 · see citing works
Animal models of sepsis and sepsis-induced kidney injury
Doi, K., Leelahavanichkul, A., Yuen, P. S. T., & Star, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39421 · Cited by 577 · see citing works
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Ferris, A. M., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41454 · Cited by 534 · see citing works
The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link
Borley, N. R., Mortensen, N. J. M., Jewell, D. P., & Warren, B. F. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200002)190:2 · Cited by 158 · see citing works
Proinflammatory and Anti-inflammatory Cytokines as Mediators in the Pathogenesis of Septic Shock
Dinarello, C. A. (1997) · CHEST Journal · doi:10.1378/chest.112.6_supplement.321s · Cited by 508 · see citing works
Pathophysiology of Sepsis
Remick, D. G. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060872 · Cited by 500 · see citing works
The American–European Consensus Conference on ARDS, Part 2: Ventilatory, Pharmacologic, Supportive Therapy, Study Design Strategies, and Issues Related to Recovery and Remodeling
Artigas, A., Bernard, G. R., Carlet, J. M., Dreyfuss, D., Gattinoni, L., Hudson, L. D., Lamy, M., Marini, J. J., Matthay, M. A., Pinsky, M. R., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.ats2-98 · Cited by 471 · see citing works
The vagus nerve and the nicotinic anti-inflammatory pathway
Ulloa, L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1797 · Cited by 467 · see citing works
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
Nigrovic, P. A., Mannion, M. L., Prince, F. H. M., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30128 · Cited by 464 · see citing works
Systemic inflammatory response syndrome
Davies, M. G., & Hagen, P.-O. (1997) · British journal of surgery · doi:10.1002/bjs.1800840707 · Cited by 488 · see citing works
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
Iskander, K. N., Osuchowski, M. F., Stearns-Kurosawa, D. J., Kurosawa, S., Stepien, D. M., Valentine, C., & Remick, D. G. (2013) · Physiological Reviews · doi:10.1152/physrev.00037.2012 · Cited by 451 · see citing works
Severe sepsis in cirrhosis†
Gustot, T., Durand, F., Lebrec, D., Vincent, J., & Moreau, R. (2009) · Hepatology · doi:10.1002/hep.23264 · Cited by 439 · see citing works
The dark side of C5a in sepsis
Ward, P. A. (2004) · Nature reviews. Immunology · doi:10.1038/nri1269 · Cited by 420 · see citing works
The Significance of Vasoactive Intestinal Peptide in Immunomodulation
Delgado, M., Pozo, D., & Ganea, D. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.7 · Cited by 412 · see citing works
“…antagonists of platelet activating factor (Dhainaut et al., 1994), antagonists of bradykinin (Fein et al., 1997), IL-1 receptor antagonists (Fisher et al., 1994), and monoclonal anti-TNF antibodies (Abraham et al., 1995) or soluble dimeric TNF receptor fusion proteins (Fisher et al., 1996).”
Background
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Ferris, A. M., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41616 · Cited by 420 · see citing works
The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome
Wang, H., & Ma, S. (2008) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2007.10.031 · Cited by 408 · see citing works
“As numerous cytokines and redundant pathways are involved in the local inflammatory response, cytokinetargeted therapy on single pathways is insufficient to improve outcomes [38-40].”
Background
The disconnect between animal models of sepsis and human sepsis
Rittirsch, D., Hoesel, L. M., & Ward, P. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0806542 · Cited by 405 · see citing works
“related mortality in large clinical trials [26].”
Prognostic and predictive enrichment in sepsis
Stanski, N. L., & Wong, H. R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0199-3 · Cited by 399 · see citing works
Animal models of sepsis
Fink, M. P. (2014) · Virulence · doi:10.4161/viru.26083 · Cited by 391 · see citing works
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
Menu, P., & Vince, J. E. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04440.x · Cited by 387 · see citing works
Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment
Ravelli, A., Grom, A. A., Behrens, E. M., & Cron, R. Q. (2012) · Genes and Immunity · doi:10.1038/gene.2012.3 · Cited by 381 · see citing works
Uncoupling of biological oscillators
Godin, P. J., & Buchman, T. G. (1996) · Critical Care Medicine · doi:10.1097/00003246-199607000-00008 · Cited by 377 · see citing works
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 375 · see citing works
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock
Reinhart, K., Wiegand-Löhnert, C., Grimminger, F., Kaul, M., Withington, S., Treacher, D., Eckart, J., Willatts, S. M., Bouza, C., Krausch, D., et al. (1996) · Critical Care Medicine · doi:10.1097/00003246-199605000-00003 · Cited by 358 · see citing works
Monocyte deactivation-rationale for a new therapeutic strategy in sepsis
Volk, H., Reinke, P., Krausch, D., Zuckermann, H., Asadullah, K., Müller, J. M., Döcke, W. ‐., & Kox, W. J. (1996) · Intensive Care Medicine · doi:10.1007/bf01743727 · Cited by 361 · see citing works
Severe Sepsis and Septic Shock: Review of the Literature and Emergency Department Management Guidelines
Nguyen, H. B., Rivers, E. P., Abrahamian, F. M., Moran, G. J., Abraham, E. H., Trzeciak, S. W., Huang, D. T., Osborn, T. M., Stevens, D. L., & Talan, D. A. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.02.015 · Cited by 354 · see citing works
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin
Bone, R. C., BALK, R. A., Fein, A. M., Perl, T. M., Wenzel, R. P., Reines, H. D., Quenzer, R. W., Iberti, T. J., MacIntyre, N. R., & Schein, R. M. H. (1995) · Critical Care Medicine · doi:10.1097/00003246-199506000-00003 · Cited by 347 · see citing works
Signaling pathways and intervention therapies in sepsis
Zhang, Y., & Ning, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00816-9 · Cited by 360 · see citing works
The Systemic Inflammatory Response to Cardiopulmonary Bypass
Hall, R. I., Stafford‐Smith, M., & Rocker, G. M. (1997) · Anesthesia & Analgesia · doi:10.1097/00000539-199710000-00011 · Cited by 407 · see citing works
Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis
Eichacker, P. Q., Parent, C., Kalil, A. C., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., & Natanson, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-302oc · Cited by 340 · see citing works
Antithrombin III in patients with severe sepsis
Eisele, B., Heinrichs, H., Delvos, U., Lamy, M., THIJS, L. G., Keinecke, H.-O., Schuster, H.-P., Matthias, F. R., & Fourrier, F. (1998) · Intensive Care Medicine · doi:10.1007/s001340050642 · Cited by 334 · see citing works
Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis
Nylén, E., Whang, K. T., Snider, R. H., et al. (1998) · Critical Care Medicine · doi:10.1097/00003246-199806000-00015 · Cited by 327 · see citing works
The changing immune system in sepsis
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2013) · Virulence · doi:10.4161/viru.26516 · Cited by 319 · see citing works
Role of Oxidative Stress and Mitochondrial Dysfunction in Sepsis and Potential Therapies
Mantzarlis, K. D., Tsolaki, V., & Zakynthinos, E. G. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/5985209 · Cited by 315 · see citing works
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
Alejandria, M. M., Lansang, M. A., Dans, L. F., & Mantaring, J. B. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001090 · Cited by 313 · see citing works
Therapeutic Neutralization of the NLRP1 Inflammasome Reduces the Innate Immune Response and Improves Histopathology after Traumatic Brain Injury
de Rivero Vaccari, J. P., Lotocki, G., Alonso, O. F., Bramlett, H. M., Dietrich, W. D., & Keane, R. W. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.46 · Cited by 312 · see citing works
“…introduced in clinical treatments of autoinflammatory diseases, such as rheumatoid arthritis or gout (Braddock and Quinn, 2004; Dinarello, 2005a; Fisher et al, 1994; Liao et al, 1984; So et al, 2007), and recent results of a phase II study of IL-1Ra treatment in stroke patients are encouraging…”
Current trends in inflammatory and immunomodulatory mediators in sepsis
Aziz, M., Jacob, A., Yang, W.-L., Matsuda, A., & Wang, P. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0912437 · Cited by 309 · see citing works
“A controversial result between LPS model and clinical trial has been noted in anti-IL-1R antibody treatment, where the murine model shows better therapeutic efficacy than patients [153, 154].”
Background
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 304 · see citing works
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
Alejandria, M. M., Lansang, M. A., Dans, L. F., & Mantaring, J. B. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001090.pub2 · Cited by 301 · see citing works
Targeting Interleukin-1 in Heart Disease
Tassell, B. W. V., Toldo, S. A., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 306 · see citing works
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Kernan, K. F., Schulert, G. S., Seo, P., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42062 · Cited by 304 · see citing works
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
Mehta, P., Cron, R. Q., Hartwell, J., Manson, J. J., & Tattersall, R. S. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30096-5 · Cited by 287 · see citing works
A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill
Atkinson, S., Sieffert, E., & Bihari, D. J. (1998) · Critical Care Medicine · doi:10.1097/00003246-199807000-00013 · Cited by 285 · see citing works
Clinical Practice Guidelines for Hospital‐Acquired Pneumonia and Ventilator‐Associated Pneumonia in Adults
Rotstein, C., Evans, G. A., Born, A., Grossman, R. F., Light, R. B., Magder, S. A., McTaggart, B., Weiss, K., & Zhanel, G. G. (2007) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/593289 · Cited by 283 · see citing works
Role of Cytokines in Sepsis
Hack, C. E., Aarden, L. A., & THUS, L. G. (1997) · Advances in immunology · doi:10.1016/s0065-2776(08)60597-0 · Cited by 284 · see citing works
Interleukin-1 function and role in rheumatic disease
Schett, G. A., Dayer, J., & Manger, B. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.166 · Cited by 278 · see citing works
Such stuff as dreams are made on: mediator-directed therapy in sepsis
Marshall, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1084 · Cited by 263 · see citing works
Clinical Gram-positive sepsis
Opal, S. M., & Cohen, J. (1999) · Critical Care Medicine · doi:10.1097/00003246-199908000-00039 · Cited by 258 · see citing works
The coagulopathy of acute sepsis
Simmons, J., & Pittet, J. (2015) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000163 · Cited by 262 · see citing works
Immune dysregulation in sepsis: experiences, lessons and perspectives
Cao, M., Wang, G., & Xie, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01766-7 · Cited by 284 · see citing works
Sepsis and serum cytokine concentrations
Damas, P., Canivet, J.-L., Groote, D. D., Vrindts, Y., Albert, A., Franchimont, P., & Lamy, M. (1997) · Critical Care Medicine · doi:10.1097/00003246-199703000-00006 · Cited by 252 · see citing works
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation
Silva, C. M. S., Wanderley, C. W. S., Veras, F. P., Sônego, F., Nascimento, D. C., Gonçalves, A. V., Martins, T. V., Colón, D. F., Borges, V. F., Brauer, V. S., et al. (2021) · Blood · doi:10.1182/blood.2021011525 · Cited by 263 · see citing works
An overview of mortality risk prediction in sepsis
Barriere, S. L., & Lowry, S. F. (1995) · Critical Care Medicine · doi:10.1097/00003246-199502000-00026 · Cited by 246 · see citing works
Strategies to improve drug development for sepsis
Fink, M. P., & Warren, H. S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4368 · Cited by 243 · see citing works
CECAL LIGATION AND PUNCTURE VERSUS COLON ASCENDENS STENT PERITONITIS: TWO DISTINCT ANIMAL MODELS FOR POLYMICROBIAL SEPSIS
Maier, S., Traeger, T., Entleutner, M., et al. (2004) · Shock · doi:10.1097/01.shk.0000126906.52367.dd · Cited by 240 · see citing works
Surgical trauma: hyperinflammation versus immunosuppression?
Menger, M. D., & Vollmar, B. (2004) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-004-0472-0 · Cited by 241 · see citing works
IL-1β suppression of VE-cadherin transcription underlies sepsis-induced inflammatory lung injury
Xiong, S., Hong, Z., Huang, L. S., Tsukasaki, Y., Nepal, S., Di, A., Zhong, M., Wu, W., Ye, Z., Gao, X., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136908 · Cited by 241 · see citing works
MYOCARDIAL DYSFUNCTION IN SEPTIC SHOCK
Kumar, A., Haery, C., & Parrillo, J. E. (2000) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70110-x · Cited by 235 · see citing works
Predicting the Duration of Mechanical Ventilation
Seneff, M. G., Zimmerman, J. E., Knaus, W. A., Wagner, D. P., & Draper, E. A. (1996) · CHEST Journal · doi:10.1378/chest.110.2.469 · Cited by 234 · see citing works
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
Cajander, S., Kox, M., Scicluna, B. P., Weigand, M. A., Mora, R. A., Flohé, S. B., Martín‐Loeches, I., Lachmann, G., Girardis, M., García‐Salido, A., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00330-2 · Cited by 248 · see citing works
Diffusive vs. convective therapy
Kellum, J. A., Johnson, J. P., Kramer, D. J., et al. (1998) · Critical Care Medicine · doi:10.1097/00003246-199812000-00027 · Cited by 226 · see citing works
Continuous plasmafiltration in sepsis syndrome
Reeves, J. H., Butt, W. W., Shann, F. A., et al. (1999) · Critical Care Medicine · doi:10.1097/00003246-199910000-00003 · Cited by 222 · see citing works
Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?
Nigrovic, P. A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38615 · Cited by 220 · see citing works
“While the risk of infection associated with anakinra use among children with systemic JIA is not well defined, it is reassuring that a large, placebo-controlled trial of several hundred adults with overt sepsis treated with anakinra at the extraordinary dose of 100 mg then 1–2 mg/kg/hour intravenously for 3 days showe…”
Background
In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling*
An, G. C. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000139707.13729.7d · Cited by 217 · see citing works
Lymphocyte function in wound healing and following injury
Schäffer, M. R., & Barbul, A. (1998) · British journal of surgery · doi:10.1046/j.1365-2168.1998.00734.x · Cited by 216 · see citing works
Pathophysiology of Sepsis-Related Cardiac Dysfunction: Driven by Inflammation, Energy Mismanagement, or Both?
Drosatos, K., Lymperopoulos, A., Kennel, P. J., Pollak, N. M., Schulze, P. C., & Goldberg, I. J. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0247-z · Cited by 216 · see citing works
Essential Role of Gamma Interferon in Survival of Colon Ascendens Stent Peritonitis, a Novel Murine Model of Abdominal Sepsis
Zantl, N., Uebe, A., Neumann, B., Wagner, H., Siewert, J., Holzmann, B., Heidecke, C.-D., & Pfeffer, K. (1998) · Infection and Immunity · doi:10.1128/iai.66.5.2300-2309.1998 · Cited by 206 · see citing works
Proteolytic Cleavage of High Mobility Group Box 1 Protein by Thrombin-Thrombomodulin Complexes
Ito, T., Kawahara, K., Okamoto, K., Yamada, S., Yasuda, M., Imaizumi, H., Nawa, Y., Meng, X., Shrestha, B., Hashiguchi, T., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.150631 · Cited by 205 · see citing works
EVALUATION OF ENDOTOXIN MODELS FOR THE STUDY OF SEPSIS
Remick, D. G., & Ward, P. A. (2005) · Shock · doi:10.1097/01.shk.0000191384.34066.85 · Cited by 201 · see citing works
An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock
Grover, R., Zaccardelli, D., Colice, G., Guntupalli, K. K., Watson, D. I., & Vincent, J. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00025 · Cited by 197 · see citing works
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1βPreprint
Shchors, K., Shchors, E., Rostker, F., Lawlor, E. R., Swigart, L. B., & Evan, G. I. (2006) · Genes & Development · doi:10.1101/gad.1455706 · Cited by 200 · see citing works
“…tumor suppressor pathways have been circumvented, both efficiently and rapidly inducing tumors with all the “hallmarks” of advanced cancers, including angiogenesis, dysplasia, suppressed apoptosis, invasion, and metastasis (Fisher et al. 1994; Pelengaris et al. 1999, 2002; Tang et al. 2005).”
Cytokines and the immunomodulatory function of the vagus nerve
Johnston, G. R., & Webster, N. R. (2009) · British Journal of Anaesthesia · doi:10.1093/bja/aep037 · Cited by 201 · see citing works
Neutrophil pyroptosis: new perspectives on sepsis
Liu, L., & Sun, B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03060-1 · Cited by 197 · see citing works
Untitled work
(1997) · doi:10.1002/(sici)1097-0142(19970501)79:9
Cerivastatin Improves Survival of Mice with Lipopolysaccharide-Induced Sepsis
Ando, H., Takamura, T., Ota, T., Nagai, Y., & Kobayashi, K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39169-4 · Cited by 192 · see citing works
Interleukin-1 blockade in cardiovascular diseases: a clinical update
Buckley, L. F., & Abbate, A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy128 · Cited by 194 · see citing works
Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome
Pacht, E. R., DeMichele, S. J., Nelson, J. L., Hart, J., Wennberg, A. K., & Gadek, J. E. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000049952.96496.3e · Cited by 191 · see citing works
“A variety of these agents include ibuprofen (48), prostaglandin E1 (49, 50), prostacyclin (51, 52), antiendotoxin antibodies (53), IL-1 receptor antagonists (54, 55), anti-TNF antibodies (56), intravenous N-acetylcysteine (57, 58), nitric oxide (59), and Ketoconazole, a thromboxane A2 synthetase inhibitor (60).”
Background
The Next Generation of Sepsis Clinical Trial Designs
Opal, S. M., Dellinger, R. P., Vincent, J., Masur, H., & Angus, D. C. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000325 · Cited by 191 · see citing works
Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status
Morgera, S., Slowinski, T., Melzer, C., et al. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.11.006 · Cited by 190 · see citing works
Prevalence of Hypophosphatemia in Sepsis and Infection: The Role of Cytokines
Barak, V., Schwartz, A., Kalickman, I., Nisman, B., Gurman, G., & Shoenfeld, Y. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00275-1 · Cited by 186 · see citing works

Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*
Meyer, N. J., Reilly, J. P., Anderson, B. J., Palakshappa, J. A., Jones, T. K., Dunn, T. G., Shashaty, M. G. S., Feng, R., Christie, J. D., & Opal, S. M. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002749 · Cited by 99 · see citing works
Studying the Pharmacokinetics of Interleukin-1RA Mutants
Khuzaima, I., Iftikhar, K., Tabarruk, U., et al. (2019) · BioScientific Review · doi:10.32350/bsr.0101.02 · Cited by 1 · see citing works
Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis
Rosenbaum, J. T. (1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080160125049 · Cited by 58 · see citing works
Role of Interleukin-1/Interleukin-1 Receptor Antagonist Family of Cytokines in Long-Term Continuous Glucose Monitoring In Vivo
Klueh, U., Antar, O. S., Qiao, Y., & Kreutzer, D. L. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700614 · Cited by 10 · see citing works
Correlation between osteoarthritis and interleukin-1 receptor antagonist
Guang-yong, G. (2007) · Yixue yanjiusheng xuebao

Authors: Fisher, C. J.
Corresponding author: Fisher, Charles J.
ORCID: Fisher, Charles J.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1994-06-15
Volume: 271
Issue: 23
Pages: 1836
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.1994.03510470040032
OpenAlex: W4322697531
Cited by: 790
References: 0
Citations by year: 2026: 11 · 2025: 23 · 2024: 18 · 2023: 28 · 2022: 15 · 2021: 18 · 2020: 32 · 2019: 23 · 2018: 24 · 2017: 22 · 2016: 19 · 2015: 18 · 2014: 30 · 2013: 20 · 2012: 22
FWCI: 37.99
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
Keywords: sepsis, septic shock, survival, organ dysfunction, mortality risk, dose-response relationship, drug safety, cytokine inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cited by

Related

Record

About these checks